Use of Recombinant Factor VII in Cardiac Surgery

Author(s): Mark Elizalde, Leonid Slobodskoy, Michael Diodato, James Chang, Edgar G. Chedrawy

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 7 , Issue 3 , 2012


The off-label use of recombinant human coagulation factor VIIa has been increasing to a number of different treatment areas since its original approval in 1999. Several US patents describe claims for FVIIa utilization in nonhemophilia patients, treatment of bleeding due to trauma, as a means to reverse major bleeding, including intracranial bleeding, induced from fibrinolytic therapy as well as a patent for using FVIIa in the treatment of bleeding for patients with bleeding disorders not caused by hemophilia, but rather bleeding disorders due to thrombocytopenia, platelet disorders, and von Willebrand’s disease. Bleeding after cardiac surgery remains a serious complication that can increase both morbidity and mortality. We review the off-label usage of recombinant factor VIIa as a hemostatic agent that may help control bleeding following cardiac surgery.

Keywords: Cardiac surgery, factor VIIa, hemostasis, off-label

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 05 November, 2012
Page: [216 - 220]
Pages: 5
DOI: 10.2174/157489012803832874
Price: $65

Article Metrics

PDF: 8